voriconazole + levofloxacin + itraconazole

This is a non-standard, unbranded combination of three pharmaceutical agents: - **Voriconazole** is a triazole antifungal that inhibits fungal cell membrane synthesis by blocking lanosterol 14-alpha-demethylase (CYP51), disrupting ergosterol production and thus inhibiting fungal growth. It is primarily used for invasive aspergillosis and other serious fungal infections. - **Levofloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination. It has broad-spectrum antibacterial activity. - **Itraconazole** is another triazole antifungal with a similar mechanism to voriconazole—blocking lanosterol 14-alpha-demethylase (CYP51)—and used for various systemic and superficial fungal infections. The combination of these drugs does not have an established brand or fixed-dose formulation; it may be considered in complex clinical scenarios such as severe or refractory infections where both broad-spectrum antibacterial and antifungal coverage are required. However, this combination carries significant risk of drug-drug interactions—especially additive QT interval prolongation—and should only be used under close medical supervision[1][3][4][5].